MNKD
Mannkind·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MNKD
Mannkind Corporation
A company that develops innovative therapeutic products for endocrine and orphan lung diseases
Biological Technology
02/14/1991
07/28/2004
NASDAQ Stock Exchange
403
12-31
Common stock
1 Casper Street, Danbury, Connecticut 06810
--
Mannkind Corporation was incorporated in Delaware on February 14, 1991. Mannkind Corporation is a biopharmaceutical company focused on the development, development and promotion of therapies and drugs such as diabetes and cancer. The company's lead product candidate, AFREZZA Inhalation Powder, is a super fast-acting insulin in late-stage clinical research for the control and treatment of hyperglycemia in adults with type 1 or type 2 diabetes. AFREZZA is loaded into insulin molecules by the company's proprietary technology circle particles. After nebulized inhalation, these loaded particles penetrate deep into the lungs using the AFREZZA inhaler. Diabetes is a major health problem.
Earnings Call
Q3/2025
Estimate EPS0.03
Actual EPS0.07
Estimate Revenue80.25M
Actual Revenue82.13M
MannKind's Q3 2025: Contradictions Emerge on Furoscix Expansion, Pricing, Afrezza Pediatric Launch, and IPF Study Timelines
Nov 05,2025 12:46
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MNKD has released its 2025 Q3 earnings. EPS was reported at 0.07, versus the expected 0.03, beating expectations. The chart below visualizes how MNKD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MNKD has released its 2025 Q3 earnings report, with revenue of 82.13M, reflecting a YoY change of 17.20%, and net profit of 7.99M, showing a YoY change of -30.87%. The Sankey diagram below clearly presents MNKD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
